Focus on human microbiome to fight liver cirrhosis
22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.
Data Hub
Contact
Privacy PolicyJoin the MICROB-PREDICT Consensus Conference at EASL Congress
We cordially invite hepatology & microbiome colleagues who attend EASL Congress 2026 in Barcelona to join the MICROB-PREDICT Consensus Conference on Wednesday, 27 May (15:30 – 18:30 h, Jansen Room). Chaired by Prof Jonel Trebicka and Prof Minneke Coenraad, the session brings together leading researchers to discuss microbiome-based mechanisms and biomarkers for improved patient stratification and therapeutic response prediction in decompensated cirrhosis and ACLF. The Consensus Conference Programme combines expert presentations and structured discussions to identify key findings, knowledge gaps, and future research priorities in this rapidly evolving field. The meeting is face-to-face (not hybrid), and participants need to be registered for EASL Congress to attend the Consensus Conference. We look forward to seeing you there!
More newsTake the 15-min MICROB-PREDICT Consensus Survey
We invite all hepatology & microbiome experts to complete a short Consensus Survey, developed in preparation for the MICROB-PREDICT Consensus Conference at EASL Congress 2026 in Barcelona. The survey (click here) only takes about 15 minutes to complete, and aims to build an evidence-informed Delphi consensus on microbiome-based mechanisms and biomarkers in decompensated cirrhosis and acute-on-chronic liver failure (ACLF), with a focus on improving patient stratification and predicting therapeutic response. It covers mechanisms and biomarkers of disease progression, the gut-liver axis, and therapeutic response to albumin, rifaximin, and terlipressin. Your contribution is highly valued and helps identify areas of consensus and uncertainty, inform expert discussions, and support future research and clinical decision-making. Responses are fully anonymised and will be analysed in aggregate only. The survey closes on 17 May 2026.
More newsMICROB-PREDICT project video
Focus on human microbiome to fight liver cirrhosis: 22 European institutions joined forces in January 2019 to improve the prevention and treatment of chronic liver disease (cirrhosis) within the MICROB-PREDICT project. We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis) and decompensated cirrhosis progresses to acute-on-chronic liver failure (ACLF), and individual treatment responses of patients. Coordinator Jonel Trebicka gives a brief overview of the project in this video.
More news